Fresenius Medical Care AG FMS
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | — | — | — | — | — | — | — | — | $12.13B | $11.41B |
| Gross profit | — | — | — | — | — | — | — | — | $5.78B | $5.33B |
| R&D | — | — | — | — | — | — | — | — | $162.4M | $140.3M |
| SG&A | — | — | — | — | — | — | — | — | $3.04B | $2.90B |
| Operating income | — | — | — | — | — | — | — | — | $2.64B | $2.33B |
| Interest expense | — | — | — | — | — | — | — | — | $452.2M | $508.0M |
| Pre-tax income | — | — | — | — | — | — | — | — | $2.23B | $1.94B |
| Income tax | — | — | — | — | — | — | — | — | $683.1M | $622.1M |
| Net income | — | — | — | — | — | — | — | — | $1.24B | $1.03B |
| EPS, basic | — | — | — | — | — | — | — | — | 4.07 | 3.38 |
| EPS, diluted | — | — | — | — | — | — | — | — | 4.06 | 3.38 |
| Shares, diluted (wtd. avg.) | — | — | — | — | — | — | — | — | 306.3M | 304.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | — | — | — | — | $2.14B | $1.96B |
| Depreciation and amortisation | — | — | — | — | — | — | — | — | $775.9M | $717.3M |
| Stock-based compensation | — | — | — | — | — | — | — | — | $25.7M | $6.6M |
| Capital expenditure | — | — | — | — | — | — | — | — | $1.03B | $952.9M |
| Investing cash flow | — | — | — | — | — | — | — | — | -$1.38B | -$1.00B |
| Financing cash flow | — | — | — | — | — | — | — | — | -$584.8M | -$1.01B |
| Dividends paid | — | — | — | — | — | — | — | — | $277.2M | $263.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-019005.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | $5.33B | $5.78B | — | — | — | — | — | — | — | — |
| Net income | $1.03B | $1.24B | — | — | — | — | — | — | — | — |
Others in SIC 8090
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DVA | DAVITA INC. | $11.72B | 18.7x | 6.5% |
| SHC | Sotera Health Co | $5.17B | 67.0x | 5.7% |
| PGNY | Progyny, Inc. | $2.22B | 44.6x | 10.4% |
| AGL | agilon health, inc. | $1.51B | — | -2.1% |
| VMD | VIEMED HEALTHCARE, INC. | $373.3M | 26.5x | 20.5% |
| BRTX | BioRestorative Therapies, Inc. | $41.3M | — | -10.3% |
| CCEL | CRYO CELL INTERNATIONAL INC | $35.9M | — | -1.3% |
| MGRX | MANGOCEUTICALS, INC. | $5.0M | — | -26.0% |